drugset / Trial / NCT01613014
ABT-436 for Alcohol Dependence
Phase 2
Completed
150 enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
AbbVie · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary efficacy endpoint examines the hypothesis that ABT-436 will decrease the weekly percentage of heavy drinking days during Study Weeks 2 through 12 (Days 8-84) as compared to placebo. A "heavy drinking day" is 4 or more drinks per drinking day for women and 5 or more drinks per drinking day for men.
Timeline
- Start
- 2013-02
- Primary completion
- 2015-05
- Completion
- 2015-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ABT-436 | Unknown | 400 mg | — |